<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Diltiazem: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i468.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i468.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i468.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i466.htm">Calcium-channel Blockers</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i466.htm" title="Previous: Calcium-channel Blockers">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i467.htm" title="Next: Verapamil">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i468">Diltiazem</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Diltiazem</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i86.htm" name="_86">Alfentanil</a></td><td> diltiazem inhibits metabolism of alfentanil (risk of prolonged or delayed respiratory depression)</td><td></td></tr><tr><td><a href="41001i118.htm" name="_118">Amiodarone</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  diltiazem given with amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td> diltiazem possibly increases plasma concentration of tricyclics </td><td></td></tr><tr><td><a href="41001i1010.htm" name="_1010">Aprepitant</a></td><td>plasma concentration of both drugs may increase when  diltiazem given with aprepitant </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  diltiazem increased by atazanavir (reduce dose of diltiazem)</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> diltiazem increases plasma concentration of atorvastatin—possible increased risk of myopathy</td><td></td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td class="cBV"><b>increased risk of AV block and bradycardia when  diltiazem given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i427.htm" name="_427">Buspirone</a></td><td> diltiazem increases plasma concentration of buspirone (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i277.htm" name="_277">Carbamazepine</a></td><td class="cBV"><b> diltiazem enhances effects of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> diltiazem increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i940.htm" name="_940">Cilostazol</a></td><td> diltiazem increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i483.htm" name="_483">Colchicine</a></td><td class="cBV"><b> diltiazem possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i618.htm">Dantrolene</a></td><td>possible increased risk of ventricular arrhythmias when  diltiazem given with <i>intravenous</i> dantrolene—manufacturer of diltiazem advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i480.htm" name="_480">Digoxin</a></td><td class="cBV"><b> diltiazem increases plasma concentration of digoxin </b></td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>increased risk of bradycardia and myocardial depression when  diltiazem given with dronedarone </b></td><td></td></tr><tr><td><a href="41001i975.htm" name="_975">Dutasteride</a></td><td> diltiazem increases plasma concentration of dutasteride </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  diltiazem reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td> diltiazem increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i1202.htm" name="_1202">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  diltiazem given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i247.htm" name="_247">Imipramine</a></td><td> diltiazem increases plasma concentration of imipramine </td><td></td></tr><tr><td><a href="41001i1050.htm" name="_1050">Ivabradine</a></td><td class="cBV"><b> diltiazem increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>neurotoxicity may occur when  diltiazem given with lithium without increased plasma concentration of lithium</td><td></td></tr><tr><td><a href="41001i492.htm" name="_492">Methylprednisolone</a></td><td> diltiazem increases plasma concentration of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm" name="_421">Midazolam</a></td><td> diltiazem inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td>plasma concentration of both drugs may increase when  diltiazem given with nifedipine </td><td></td></tr><tr><td><a href="41001i284.htm" name="_284">Phenytoin</a></td><td class="cBV"><b> diltiazem increases plasma concentration of phenytoin but also effect of diltiazem reduced</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td> diltiazem increases plasma concentration of ranolazine (consider reducing dose of ranolazine)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  diltiazem accelerated by rifampicin (plasma concentration significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> diltiazem increases plasma concentration of simvastatin—possible increased risk of myopathy</td><td></td></tr><tr><td><a href="41001i921.htm" name="_921">Sirolimus</a></td><td class="cBV"><b> diltiazem increases plasma concentration of sirolimus </b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> diltiazem increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td>caution with  diltiazem advised by manufacturer of telaprevir </td><td></td></tr><tr><td><a href="41001i734.htm" name="_734">Theophylline</a></td><td> diltiazem increases plasma concentration of theophylline </td><td></td></tr><tr><td><a href="41001i1203.htm" name="_1203">Ticagrelor</a></td><td> diltiazem increases plasma concentration of ticagrelor </td><td></td></tr></tbody></table><p>Diltiazem belongs to <b>Calcium-channel Blockers</b>
          and will have the following interactions:
        </p><div>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







































<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with alcohol </td><td></td></tr><tr><td><a href="41001i21.htm">Aldesleukin</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with aldesleukin </td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td class="cBV"><b>enhanced hypotensive effect when  calcium-channel blockers given with alpha-blockers , also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin</b></td><td></td></tr><tr><td><a href="41001i681.htm">Alprostadil</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with alprostadil </td><td></td></tr><tr><td><a href="41001i39.htm">Anaesthetics, General</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with general anaesthetics </td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with baclofen </td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  calcium-channel blockers possibly inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>metabolism of  calcium-channel blockers possibly inhibited by clarithromycin (increased risk of side-effects)</b></td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with clonidine </td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>hypotensive effect of  calcium-channel blockers antagonised by corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with diuretics </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>metabolism of  calcium-channel blockers possibly inhibited by erythromycin (increased risk of side-effects)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with hydralazine </td><td></td></tr><tr><td><a href="41001i50.htm">Isoflurane</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with isoflurane </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>negative inotropic effect possibly increased when  calcium-channel blockers given with itraconazole </td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with levodopa </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with MAOIs </td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td>possible increased risk of bradycardia when  calcium-channel blockers given with mefloquine </td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with minoxidil </td><td></td></tr><tr><td><a href="41001i806.htm">Moxisylyte</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with moxisylyte </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with moxonidine </td><td></td></tr><tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td> calcium-channel blockers possibly enhance effects of non-depolarising muscle relaxants </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with nitrates </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td>hypotensive effect of  calcium-channel blockers antagonised by NSAIDs </td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>hypotensive effect of  calcium-channel blockers antagonised by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>effects of  calcium-channel blockers probably reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  calcium-channel blockers possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>metabolism of  calcium-channel blockers possibly inhibited by telithromycin (increased risk of side-effects)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> calcium-channel blockers possibly increase plasma concentration of theophylline (enhanced effect)</b></td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td>enhanced hypotensive effect when  calcium-channel blockers given with tizanidine </td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i466.htm">Previous: Calcium-channel Blockers</a> | <a class="top" href="41001i468.htm#">Top</a> | <a accesskey="]" href="41001i467.htm">Next: Verapamil</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>